A detailed history of Amalgamated Bank transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 1,571 shares of ALDX stock, worth $7,525. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,571
Previous 1,571 -0.0%
Holding current value
$7,525
Previous $5,000 60.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$2.77 - $4.22 $13,913 - $21,197
-5,023 Reduced 76.18%
1,571 $5,000
Q4 2023

Feb 06, 2024

SELL
$1.47 - $6.06 $686 - $2,830
-467 Reduced 6.61%
6,594 $23,000
Q2 2023

Aug 11, 2023

BUY
$7.11 - $11.89 $50,203 - $83,955
7,061 New
7,061 $59,000
Q2 2022

Aug 15, 2022

SELL
$2.43 - $4.85 $19,265 - $38,450
-7,928 Closed
0 $0
Q1 2022

Jun 30, 2022

BUY
$3.25 - $5.17 $25,766 - $40,987
7,928 New
7,928 $35,000

Others Institutions Holding ALDX

About Aldeyra Therapeutics, Inc.


  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $279M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.